Dataset Information


?-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1.

ABSTRACT: Glioma is the most frequent primary central nervous system tumor. Although the current first-line medicine, temozolomide (TMZ), promotes patient survival, drug resistance develops easily. Thus, it is important to investigate novel therapeutic reagents to solidify the treatment effect. ?-Elemene (bELE) is a compound from a Chinese herb whose anticancer effect has been shown in various types of cancer. However, its role in the inhibition of glioma stem-like cells (GSLCs) has not yet been reported. We studied both the in vitro and the in vivo inhibitory effect of bELE and TMZ in GSLCs and parental cells and their combined effects. The molecular mechanisms were also investigated. We also optimized the delivery methods of bELE. We found that bELE selectively inhibits the proliferation and sphere formation of GSLCs, other than parental glioma cells, and TMZ exerts its effects on parental cells instead of GSLCs. The in vivo data confirmed that the combination of bELE and TMZ worked better in the xenografts of GSLCs, mimicking the situation of tumorigenesis of human cancer. Notch1 was downregulated with bELE treatment. Our data also demonstrated that the continuous administration of bELE produces an ideal effect to control tumor progression. Our findings have demonstrated, for the first time, that bELE could compensate for TMZ to kill both GSLCs and nonstem-like cancer cells, probably improving the prognosis of glioma patients tremendously. Notch1 might be a downstream target of bELE. Therefore, our data shed light on improving the outcomes of glioma patients by combining bELE and TMZ. Stem Cells Translational Medicine 2017;6:830-839.


PROVIDER: S-EPMC5442766 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4751482 | BioStudies
1000-01-01 | S-EPMC6186893 | BioStudies
2020-01-01 | S-EPMC7474225 | BioStudies
2019-01-01 | S-EPMC6347285 | BioStudies
1000-01-01 | S-EPMC4369819 | BioStudies
2018-01-01 | S-EPMC5891203 | BioStudies
2020-01-01 | S-EPMC7163451 | BioStudies
2020-01-01 | S-EPMC7277271 | BioStudies
2019-01-01 | S-EPMC6392088 | BioStudies
2016-01-01 | S-EPMC4914333 | BioStudies